Allergy Vaccine

Scientists have developed a new vaccine against cat allergiesPHARMACY oline based on Nature materials

Numerous studies have proved that allergy to cats is the result of the work of specific antibodies – IgE immunoglobulins, which, released in response to the ingestion of antigen into the body, stimulate the degranulation of basophils and the development of inflammation. This whole mechanism is triggered by the so–called feline antigen - Fel D1.

Modern methods of treating this allergy include, in addition to antihistamine therapy, subcutaneous injections of antigen in order to "train" the immune system to prevent the production of IgE in response to Fel D1. However, this type of therapy has a significant drawback: it is often ineffective and leads to reactivation of IgE production.

Researchers from Cytos Biotechnology decided to look for a way to deliver the antigen directly to the cells of the immune system in such a way as to exclude the production of IgE immunoglobulins. Scientists have developed a new vaccine, which is a combination of "cat antigen" with viral particles. Once in the body, this construct is recognized by the immune system as a virus and causes the production of protective IgG immunoglobulins. The results of the studies published in the journal of Experimental Medicine confirmed that the basophils taken from volunteers did not degranulate after treatment with the antigen-viral construct, unlike treatment with pure Fel D1 antigen. Wild-type mice injected with the antigen-viral construct showed a strong immune response, expressed in IgG superfoods. After the administration of pure antigen to these mice, the researchers noted a complete absence of allergic reactions to it, which confirmed their conclusions.

Despite the obvious positive effects of the vaccine, researchers have not yet come to a consensus on the mechanisms of its action. Possible explanations include activation of Fc-gamma receptor IIb, as a result of which IgE immunoglobulins cannot interact with basophils and mast cells, as well as activation of T cells.

Currently, Cytos Biotechnology has managed to obtain a patent for the vaccine and the method by which it was developed. According to the company's representatives, the technology is open for partnership.

Portal "Eternal youth" http://vechnayamolodost.ru28.08.2009